<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00142337</url>
  </required_header>
  <id_info>
    <org_study_id>IRD-UMI 174 PHPT-4</org_study_id>
    <nct_id>NCT00142337</nct_id>
  </id_info>
  <brief_title>One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine</brief_title>
  <official_title>A Phase 2, One Arm, Open Label, Feasibility Study Assessing One Month Zidovudine/Didanosine Postpartum Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine to Prevent Mother to Child Transmission of HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether providing zidovudine (ZDV) and didanosine
      (ddI) during labor and for one month postpartum can reduce the selection of nevirapine (NVP)
      resistance mutations postpartum in women who received a single dose of nevirapine during
      labor and standard ZDV prophylaxis for the prevention of mother to child transmission of HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single nevirapine dose to the mother, with or without a dose to the child, in addition to
      oral ZDV prophylaxis starting from 28 weeks gestation has been proven to be highly effective
      in reducing further mother-to-child HIV transmission (PMTCT).

      However, post exposure nevirapine resistance mutations are observed in the mother's viral
      population. These mutations detectable very early after exposure tend to disappear over time.

      Nevertheless, they may be associated with decrease in efficacy of non-nucleoside reverse
      transcriptase inhibitor (NNRTI) containing regimens subsequently given to the women for their
      own health.

      Therefore, there is a need for research to prevent selection of resistance in the first place
      or to overcome the resistance in subsequent treatment of the infected mother or infant.

      Nevirapine plasma levels above IC50 have been detected in women exposed to a single 200 mg
      dose of nevirapine in a significant number of women during the third week postpartum.

      We hypothesize that giving ZDV+ddI to women exposed to nevirapine for one month as soon as
      possible after exposure may prevent the selection of nevirapine resistance mutations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with viral NNRTI mutations detectable during the 4 month follow-up compared with the incidence observed in the PHPT-2 clinical trial, who received the same antiretroviral prophylaxis but no post-partum regimen</measure>
    <time_frame>Within 4 months postpartum</time_frame>
  </primary_outcome>
  <enrollment type="Actual">244</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine (ZDV)</intervention_name>
    <description>Zidovudine 300 mg, twice daily, for one month postpartum. Note: after July 03, 2005, all women received 200 mg, twice daily, for the same duration.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine (ddI)</intervention_name>
    <description>250 mg ddI-EC (400 mg if body weight &gt;60 kg) once daily, starting at the onset of labor and for one month postpartum</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet all pre-entry criteria;

          -  Consent to participate and to be followed for the duration of the study;

          -  Present the following laboratory values within 14 days prior to inclusion:

               -  Hemoglobin &gt; 8.0 mg/dl

               -  Absolute neutrophil count &gt; 1000 cells/mm3

               -  Platelets &gt; 100,000 cells/mm3

               -  Serum creatinine &lt; 1.5 mg/dl (women with a serum creatinine &gt; 1.5 mg/dl must have
                  a measured eight-hour urine creatinine clearance &gt; 70 ml/min)

               -  SGPT less than 10 times the upper limit of normal

               -  Amylase less than 150/L IU (this upper limit may change slightly depending on the
                  normal range at the hospital laboratory).

        Exclusion Criteria:

          -  Evidence of pre-existing fetal anomalies incompatible with life;

          -  Known hypersensitivity to any benzodiazepine or to NVP;

          -  Receipt of antiretroviral agent other than ZDV;

          -  Receipt of non-allowed concomitant treatment or contraindication to ddI

          -  Concurrent participation in another clinical trial;

          -  Women with a CD4 count &lt;200/ÂµL or history of oral candidiasis if they are not
             receiving pneumocystis carinii pneumonia (PCP) prophylaxis

          -  Any other contra-indicated drugs during ZDV+ddI treatment for the mother as well as
             the child (Contra-indicated drugs such as gancyclovir, isoniazid, linezolid,
             ethambutol, rifabutin, cidofovir are not allowed during the ZDV ddI treatment after
             delivery in order to prevent pharmacological interactions or overlapping toxicities.)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Lallemant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recherche pour le Developpement</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chacheongsao Hospital</name>
      <address>
        <city>Muang</city>
        <state>Chacheongsao</state>
        <zip>24000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prapokklao Hospital</name>
      <address>
        <city>Muang</city>
        <state>Chantaburi</state>
        <zip>22000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakornping Hospital</name>
      <address>
        <city>Mae Rim</city>
        <state>Chiang Mai</state>
        <zip>50180</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Promotion Center Region 10</name>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <zip>50100</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lamphun Hospital</name>
      <address>
        <city>Munag</city>
        <state>Chiang Mai</state>
        <zip>51000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mae Chan Hospital</name>
      <address>
        <city>Mae Chan</city>
        <state>Chiang Rai</state>
        <zip>57110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mae Sai Hospital</name>
      <address>
        <city>Mae Sai</city>
        <state>Chiang Rai</state>
        <zip>57130</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phan Hospital</name>
      <address>
        <city>Phan</city>
        <state>Chiang Rai</state>
        <zip>57120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital</name>
      <address>
        <city>Muang</city>
        <state>Chiangrai</state>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonburi Hospital</name>
      <address>
        <city>Muang</city>
        <state>Chonburi</state>
        <zip>20000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalasin Hospital</name>
      <address>
        <city>Muang</city>
        <state>Kalasin</state>
        <zip>46000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phaholpolphayuhasena Hospital</name>
      <address>
        <city>Munag</city>
        <state>Kanjanaburi</state>
        <zip>71000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kranuan Crown Prince Hospital</name>
      <address>
        <city>Kranuan</city>
        <state>Khon Kaen</state>
        <zip>40170</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khon Kaen Hospital</name>
      <address>
        <city>Muang</city>
        <state>Khon Kaen</state>
        <zip>40000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Health Promotion Centre 6, Khon Kaen</name>
      <address>
        <city>Muang</city>
        <state>Khon Kaen</state>
        <zip>40000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Muang</city>
        <state>Khon Kaen</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lampang Hospital</name>
      <address>
        <city>Muang</city>
        <state>Lampang</state>
        <zip>52000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakhonpathom Hospital</name>
      <address>
        <city>Muang</city>
        <state>Nakhonpathom</state>
        <zip>73000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakornratchasrima Hospital</name>
      <address>
        <city>Muang</city>
        <state>Nakornratchasrima</state>
        <zip>30000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nong Khai Hospital</name>
      <address>
        <city>Muang</city>
        <state>Nong Kai</state>
        <zip>43000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pranangklao Hospital</name>
      <address>
        <city>Muang</city>
        <state>Nonthaburi</state>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Kham Hospital</name>
      <address>
        <city>Chiang Kham</city>
        <state>Phayao</state>
        <zip>56110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddhachinaraj Hospital</name>
      <address>
        <city>Muang</city>
        <state>Pitsanuloke</state>
        <zip>65000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ratchaburi Hospital</name>
      <address>
        <city>Muang</city>
        <state>Ratchaburi</state>
        <zip>70000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rayong Hospital</name>
      <address>
        <city>Muang</city>
        <state>Rayong</state>
        <zip>21000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roi-et Hospital</name>
      <address>
        <city>Muang</city>
        <state>Roi-et</state>
        <zip>45000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samutsakorn Hospital</name>
      <address>
        <city>Muang</city>
        <state>Samutsakorn</state>
        <zip>74000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hat Yai Hospital</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhumibol Adulyadej Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10220</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Promotion Hospital Regional Center I</name>
      <address>
        <city>Bangkok</city>
        <zip>10220</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somdej Pranangchao Sirikit Hospital</name>
      <address>
        <city>Chonburi</city>
        <zip>20180</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samutprakarn Hospital</name>
      <address>
        <city>Samutprakarn</city>
        <zip>10280</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, Kanshana S, McIntosh K, Thaineua V; Perinatal HIV Prevention Trial (Thailand) Investigators. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004 Jul 15;351(3):217-28. Epub 2004 Jul 9.</citation>
    <PMID>15247338</PMID>
  </reference>
  <reference>
    <citation>Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S, Lallemant M; Perinatal HIV Prevention Trial Group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004 Jul 15;351(3):229-40. Epub 2004 Jul 9.</citation>
    <PMID>15247339</PMID>
  </reference>
  <reference>
    <citation>Cressey TR, Jourdain G, Lallemant MJ, Kunkeaw S, Jackson JB, Musoke P, Capparelli E, Mirochnick M. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):283-8.</citation>
    <PMID>15735445</PMID>
  </reference>
  <results_reference>
    <citation>Lallemant M, Ngo-Giang-Huong N, Jourdain G, Traisaithit P, Cressey TR, Collins IJ, Jarupanich T, Sukhumanant T, Achalapong J, Sabsanong P, Chotivanich N, Winiyakul N, Ariyadej S, Kanjanasing A, Ratanakosol J, Hemvuttiphan J, Kengsakul K, Wannapira W, Sittipiyasakul V, Pornkitprasarn W, Liampongsabuddhi P, McIntosh K, Van Dyke RB, Frenkel LM, Koetsawang S, Le Coeur S, Kanchana S; PHPT-4 Study Team. Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine. Clin Infect Dis. 2010 Mar 15;50(6):898-908. doi: 10.1086/650745.</citation>
    <PMID>20158398</PMID>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>January 4, 2012</last_update_submitted>
  <last_update_submitted_qc>January 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Recherche pour le Developpement</investigator_affiliation>
    <investigator_full_name>Marc Lallemant</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <keyword>zidovudine</keyword>
  <keyword>didanosine</keyword>
  <keyword>Prevention of mother to child transmission of HIV</keyword>
  <keyword>nevirapine</keyword>
  <keyword>Thailand</keyword>
  <keyword>Resistance</keyword>
  <keyword>HIV</keyword>
  <keyword>Postpartum period</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

